Sixty-three outpatients with chronic insomnia were treated for 3 weeks under double-blind conditions with either brotizolam (n = 29) at a dose of 0.25 mg or 0.5 mg or placebo (n = 34). A 3-day placebo period preceded and followed the double-blind treatment phase. Brotizolam consistently produced significantly more sleep improvement than placebo but also more adverse effects. In those patients switched abruptly from brotizolam to placebo, rebound insomnia was observed, being most marked at the first post-brotizolam placebo night.
In an earlier study this research group reported iprindole, a relatively new tricyclic derivative, to be an effective drug for use in depressed neurotic out-patients (ii). We found it to produce significantly greater improvement than placebo on a variety of outcome measures. Good response to iprindole as compared to placebo has also been reported by Hicks (5) and Daneman (3). Sterlin et al., comparing iprindole with amitriptyline in a relatively small patient sample, reported that iprindole, while faster acting, produced less overall improvement (15); differences in improvement did not, however, reach statistical significance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.